The present invention provides improved solvents, methods, and systems for isolating purified cannabinoids from various sources. It has been found that C.sub.9 to C.sub.11 non-aromatic hydrocarbon solvents, and especially n-decane, work surprisingly well for crystallization of cannabinoids such as cannabidiol. Some variations provide a method of isolating cannabinoids from a cannabinoid-containing solution, comprising contacting the solution with a C.sub.9-C.sub.11 non-aromatic hydrocarbon solvent (e.g., n-decane) at a first temperature, to generate a mixture; cooling the mixture to precipitate cannabinoids; and isolating the precipitated cannabinoids. Other variations provide a method of isolating cannabinoids from a cannabinoid-containing solution, comprising contacting the solution with a C.sub.9-C.sub.11 non-aromatic hydrocarbon solvent (e.g., n-decane) at a first temperature below the solvent boiling point, to generate a mixture; subjecting the mixture to a second temperature that causes vaporization of the solvent, to precipitate at least some of the cannabinoids; and isolating the precipitated cannabinoids.

A method for purification and separation of cannabinoids, such as cannabidiol and tetrahydrocannabinol, e.g., from dried hemp and cannabis leaves can use a continuous simulated moving bed process, a batch column chromatography method, or a single column, and a combination of one or more of a sequence of purification steps including: filtration, decolorization, activation or decarboxylation, dewaxing, polishing, and crystallization to separate a cannabinoid from the cannabis plant and to provide various cannabinoid products. The cannabinoid products can be used in various pharmaceutical and nutraceutical applications.

A method for purification and separation of cannabinoids, such as cannabidiol and tetrahydrocannabinol, e.g., from dried hemp and cannabis leaves can use a continuous simulated moving bed process, a batch column chromatography method, or a single column, and a combination of one or more of a sequence of purification steps including: filtration, decolorization, activation or decarboxylation, dewaxing, polishing, and crystallization to separate a cannabinoid from the cannabis plant and to provide various cannabinoid products. The cannabinoid products can be used in various pharmaceutical and nutraceutical applications.

The present invention relates to crystalline polymorphs of Tapinarof, e.g., Tapinarof crystalline Form B, Form C, and Form D, pharmaceutical compositions comprising the same, processes for preparation thereof, and uses thereof for treatment of skin disorders.

The present invention relates to crystalline polymorphs of Tapinarof, e.g., Tapinarof crystalline Form B, Form C, and Form D, pharmaceutical compositions comprising the same, processes for preparation thereof, and uses thereof for treatment of skin disorders.

A method for producing bisphenol A (BPA) is provided. The method includes step A of degrading a polycarbonate resin in a solvent and distilling off the solvent to obtain a crude solution A; step B of subjecting acetone and phenol to dehydration condensation; step C of distilling off unreacted acetone and water to obtain a concentrated liquid C; step D of crystallizing the concentrated liquid C to obtain a slurry liquid, from which a mother liquor D is obtained; step H of obtaining a solution H1 or a solution H2 from the crude solution A and part of the mother liquor D; and step I of supplying the solution H1 or H2 to the step B or C. The solution H1 contains BPA obtained by degrading BPA contained in the crude solution A and the mother liquor D into phenol and isopropenylphenol and then rebonding phenol and isopropenylphenol, and the solution H2 contains phenol obtained by degrading BPA contained in the crude solution A and the mother liquor D into phenol and acetone.

A method for producing bisphenol A (BPA) is provided. The method includes step A of degrading a polycarbonate resin in a solvent and distilling off the solvent to obtain a crude solution A; step B of subjecting acetone and phenol to dehydration condensation; step C of distilling off unreacted acetone and water to obtain a concentrated liquid C; step D of crystallizing the concentrated liquid C to obtain a slurry liquid, from which a mother liquor D is obtained; step H of obtaining a solution H1 or a solution H2 from the crude solution A and part of the mother liquor D; and step I of supplying the solution H1 or H2 to the step B or C. The solution H1 contains BPA obtained by degrading BPA contained in the crude solution A and the mother liquor D into phenol and isopropenylphenol and then rebonding phenol and isopropenylphenol, and the solution H2 contains phenol obtained by degrading BPA contained in the crude solution A and the mother liquor D into phenol and acetone.

The subject invention pertains to cocrystals of dexamethasone (DEX) and a benzenediol cocrystal composed of a 1:1 molar ratio of DEX and the benzenediol. The benzenediol can be catechol (CAT) or resorcinol (RES). The DEX and benzenediol cocrystal are formed by grinding crystalline DEX where the crystalline benzenediol are combined in the 1:1 molar ratio. Grinding can be performed at room temperature. Cocrystals can be thermally annealed or exposed to humidity to enhance cocrystal formation. The DEX−CAT or DEX-RES cocrystals can be included in a medicament for use in treatments for allergies, asthma, rhinitis, cancer, diabetes, anemia, ulcers, and viral infections. The DEX−benzenediol cocrystal can be sieved to provide particles that are in the range of 10 to 45 μm that can be used for intranasal administration with improved dissolution performance.

The subject invention pertains to cocrystals of dexamethasone (DEX) and a benzenediol cocrystal composed of a 1:1 molar ratio of DEX and the benzenediol. The benzenediol can be catechol (CAT) or resorcinol (RES). The DEX and benzenediol cocrystal are formed by grinding crystalline DEX where the crystalline benzenediol are combined in the 1:1 molar ratio. Grinding can be performed at room temperature. Cocrystals can be thermally annealed or exposed to humidity to enhance cocrystal formation. The DEX−CAT or DEX-RES cocrystals can be included in a medicament for use in treatments for allergies, asthma, rhinitis, cancer, diabetes, anemia, ulcers, and viral infections. The DEX−benzenediol cocrystal can be sieved to provide particles that are in the range of 10 to 45 μm that can be used for intranasal administration with improved dissolution performance.

The present invention provides improved solvents, methods, and systems for isolating purified cannabinoids from various sources. It has been found that C.sub.9 to C.sub.11 non-aromatic hydrocarbon solvents, and especially n-decane, work surprisingly well for crystallization of cannabinoids such as cannabidiol. Some variations provide a method of isolating cannabinoids from a cannabinoid-containing solution, comprising contacting the solution with a C.sub.9-C.sub.11 non-aromatic hydrocarbon solvent (e.g., n-decane) at a first temperature, to generate a mixture; cooling the mixture to precipitate cannabinoids; and isolating the precipitated cannabinoids. Other variations provide a method of isolating cannabinoids from a cannabinoid-containing solution, comprising contacting the solution with a C.sub.9-C.sub.11 non-aromatic hydrocarbon solvent (e.g., n-decane) at a first temperature below the solvent boiling point, to generate a mixture; subjecting the mixture to a second temperature that causes vaporization of the solvent, to precipitate at least some of the cannabinoids; and isolating the precipitated cannabinoids.